Isentress shows efficacy in treatment-naive HIV
This article was originally published in Scrip
Merck & Co's first-in-class HIV integrase inhibitor, Isentress (raltegravir), can reduce viral load to undetectable levels with a responder rate comparable with that of efavirenz (a standard of care) in treatment-naive HIV patients, new Phase III data show. The results were presented at the recent joint Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America in Washington, DC.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.